Juvenile myelomonocytic leukemia relapsing after allogeneic bone marrow transplantation successfully treated with interferon-alpha. 2000

H Ohta, and M Kawai, and A Sawada, and S Tokimasa, and H Fujisaki, and Y Matsuda, and Y Osugi, and S Okada, and J Hara
Department of Developmental Medicine (Pediatrics), Osaka Utniversihv Graduate School of Medicine, Suita, Japan.

We report a 5-year-old boy with juvenile myelomonocytic leukemia (JMML) which relapsed after an allogeneic bone marrow transplant who was successfully treated with interferon-alpha (IFN-alpha). One year after starting the therapy, he remains clinically well and in complete remission while continuing treatment with IFN-alpha and bestatin. Although the precise mechanism by which remission was induced is uncertain, a GVL effect combined with a direct antileukemia effect of IFN-alpha may be responsible. Further assessment of the role of IFN-alpha in relapsed JMLL patients is warranted.

UI MeSH Term Description Entries
D008297 Male Males
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D015477 Leukemia, Myelomonocytic, Chronic A myelodysplastic-myeloproliferative disease characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood. Myelomonocytic Leukemia, Chronic,Chronic Myelomonocytic Leukemia,Chronic Myelomonocytic Leukemias,Leukemia, Chronic Myelomonocytic,Leukemias, Chronic Myelomonocytic,Myelomonocytic Leukemias, Chronic
D016026 Bone Marrow Transplantation The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION. Bone Marrow Cell Transplantation,Grafting, Bone Marrow,Transplantation, Bone Marrow,Transplantation, Bone Marrow Cell,Bone Marrow Grafting
D016898 Interferon-alpha One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways. Interferon Alfa,Interferon, Leukocyte,Interferon, Lymphoblast,alpha-Interferon,IFN-alpha D,IFN-alpha5,Interferon alpha-1,Interferon alpha-17,Interferon alpha-4,Interferon alpha-5,Interferon alpha-7,Interferon alpha-88,Interferon alpha-J,Interferon alpha-T,Interferon alpha4,Interferon alpha5,Interferon, Lymphoblastoid,Interferon, alpha,LeIF I,LeIF J,Leif D,IFN alpha D,IFN alpha5,Interferon alpha,Interferon alpha 1,Interferon alpha 17,Interferon alpha 4,Interferon alpha 5,Interferon alpha 7,Interferon alpha 88,Interferon alpha J,Interferon alpha T,Leukocyte Interferon,Lymphoblast Interferon,Lymphoblastoid Interferon,alpha Interferon
D020544 Graft vs Leukemia Effect Immunological rejection of leukemia cells following bone marrow transplantation. Graft vs Leukemia Response,Graft-vs-Leukemia Effect,Graft-vs-Leukemia Response,Effect, Graft-vs-Leukemia,Effects, Graft-vs-Leukemia,Graft-vs-Leukemia Effects,Graft-vs-Leukemia Responses,Response, Graft-vs-Leukemia,Responses, Graft-vs-Leukemia

Related Publications

H Ohta, and M Kawai, and A Sawada, and S Tokimasa, and H Fujisaki, and Y Matsuda, and Y Osugi, and S Okada, and J Hara
March 1999, Bone marrow transplantation,
H Ohta, and M Kawai, and A Sawada, and S Tokimasa, and H Fujisaki, and Y Matsuda, and Y Osugi, and S Okada, and J Hara
June 1994, Bone marrow transplantation,
H Ohta, and M Kawai, and A Sawada, and S Tokimasa, and H Fujisaki, and Y Matsuda, and Y Osugi, and S Okada, and J Hara
June 1997, Bone marrow transplantation,
H Ohta, and M Kawai, and A Sawada, and S Tokimasa, and H Fujisaki, and Y Matsuda, and Y Osugi, and S Okada, and J Hara
April 2000, International journal of hematology,
H Ohta, and M Kawai, and A Sawada, and S Tokimasa, and H Fujisaki, and Y Matsuda, and Y Osugi, and S Okada, and J Hara
March 2004, Journal of pediatric hematology/oncology,
H Ohta, and M Kawai, and A Sawada, and S Tokimasa, and H Fujisaki, and Y Matsuda, and Y Osugi, and S Okada, and J Hara
November 1988, Presse medicale (Paris, France : 1983),
H Ohta, and M Kawai, and A Sawada, and S Tokimasa, and H Fujisaki, and Y Matsuda, and Y Osugi, and S Okada, and J Hara
November 1992, [Rinsho ketsueki] The Japanese journal of clinical hematology,
H Ohta, and M Kawai, and A Sawada, and S Tokimasa, and H Fujisaki, and Y Matsuda, and Y Osugi, and S Okada, and J Hara
January 1990, European journal of haematology. Supplementum,
H Ohta, and M Kawai, and A Sawada, and S Tokimasa, and H Fujisaki, and Y Matsuda, and Y Osugi, and S Okada, and J Hara
April 1998, Blood,
H Ohta, and M Kawai, and A Sawada, and S Tokimasa, and H Fujisaki, and Y Matsuda, and Y Osugi, and S Okada, and J Hara
April 2004, Bone marrow transplantation,
Copied contents to your clipboard!